
News|Videos|November 16, 2023
Polatuzumab Vedotin in DLBCL: Trial Data and Treatment Strategies
Author(s)Matthew A. Lunning, DO, FACP
A deep dive into the use of Polatuzumab Vedotin in DLBCL treatment, including insights from clinical trials and innovative strategies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5










































